| Dr Eric Stein Bronsky, MD | |
|
411 West Randolph Rd, John Randolph Medical Center, Hopewell, VA 23860 | |
| (804) 541-7505 | |
| Not Available |
| Full Name | Dr Eric Stein Bronsky |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 411 West Randolph Rd, Hopewell, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760402895 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 44661 (Colorado) | Secondary |
| 207P00000X | Emergency Medicine | 0101237631 (Virginia) | Primary |
| Entity Name | Vail Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992812333 PECOS PAC ID: 3577475714 Enrollment ID: O20031105000224 |
News Archive
The research is part of a 20-year study by the ANU Centre for Mental Health Research called PATH Through Life and suggests a revision of long-standing views on the impact of age-related brain shrinkage.
BioMarker Strategies received a $1.5 million SBIR award to develop a pathway-based companion diagnostic test to facilitate the selection of optimal therapy for patients with melanoma. This award was preceded by an NCI award of $200,000 almost two years ago in September 2011.
Research led by SUNY Downstate Medical Center has identified a brain receptor that appears to initiate adolescent synaptic pruning, a process believed necessary for learning, but one that appears to go awry in both autism and schizophrenia.
AstraZeneca today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS).
Johns Hopkins scientists have identified a molecular marker called "Mig 6" that appears to accurately predict longer survival - up to two years - among patients prescribed two of the most widely used drugs in a class of anticancer agents called EGFR inhibitors.
› Verified 5 days ago
| Entity Name | Catholic Health Initiatives Colorado |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356783351 PECOS PAC ID: 8022927342 Enrollment ID: O20031215000462 |
News Archive
The research is part of a 20-year study by the ANU Centre for Mental Health Research called PATH Through Life and suggests a revision of long-standing views on the impact of age-related brain shrinkage.
BioMarker Strategies received a $1.5 million SBIR award to develop a pathway-based companion diagnostic test to facilitate the selection of optimal therapy for patients with melanoma. This award was preceded by an NCI award of $200,000 almost two years ago in September 2011.
Research led by SUNY Downstate Medical Center has identified a brain receptor that appears to initiate adolescent synaptic pruning, a process believed necessary for learning, but one that appears to go awry in both autism and schizophrenia.
AstraZeneca today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS).
Johns Hopkins scientists have identified a molecular marker called "Mig 6" that appears to accurately predict longer survival - up to two years - among patients prescribed two of the most widely used drugs in a class of anticancer agents called EGFR inhibitors.
› Verified 5 days ago
| Entity Name | Usacs Of Colorado Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760415871 PECOS PAC ID: 4981507571 Enrollment ID: O20040130000439 |
News Archive
The research is part of a 20-year study by the ANU Centre for Mental Health Research called PATH Through Life and suggests a revision of long-standing views on the impact of age-related brain shrinkage.
BioMarker Strategies received a $1.5 million SBIR award to develop a pathway-based companion diagnostic test to facilitate the selection of optimal therapy for patients with melanoma. This award was preceded by an NCI award of $200,000 almost two years ago in September 2011.
Research led by SUNY Downstate Medical Center has identified a brain receptor that appears to initiate adolescent synaptic pruning, a process believed necessary for learning, but one that appears to go awry in both autism and schizophrenia.
AstraZeneca today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS).
Johns Hopkins scientists have identified a molecular marker called "Mig 6" that appears to accurately predict longer survival - up to two years - among patients prescribed two of the most widely used drugs in a class of anticancer agents called EGFR inhibitors.
› Verified 5 days ago
| Entity Name | Usacs Observation Medicine Services Of Colorado Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518491232 PECOS PAC ID: 9133498074 Enrollment ID: O20170707002144 |
News Archive
The research is part of a 20-year study by the ANU Centre for Mental Health Research called PATH Through Life and suggests a revision of long-standing views on the impact of age-related brain shrinkage.
BioMarker Strategies received a $1.5 million SBIR award to develop a pathway-based companion diagnostic test to facilitate the selection of optimal therapy for patients with melanoma. This award was preceded by an NCI award of $200,000 almost two years ago in September 2011.
Research led by SUNY Downstate Medical Center has identified a brain receptor that appears to initiate adolescent synaptic pruning, a process believed necessary for learning, but one that appears to go awry in both autism and schizophrenia.
AstraZeneca today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS).
Johns Hopkins scientists have identified a molecular marker called "Mig 6" that appears to accurately predict longer survival - up to two years - among patients prescribed two of the most widely used drugs in a class of anticancer agents called EGFR inhibitors.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Eric Stein Bronsky, MD 3805 Hill Monument Pkwy, Richmond, VA 23227-3905 Ph: (804) 523-7969 | Dr Eric Stein Bronsky, MD 411 West Randolph Rd, John Randolph Medical Center, Hopewell, VA 23860 Ph: (804) 541-7505 |
News Archive
The research is part of a 20-year study by the ANU Centre for Mental Health Research called PATH Through Life and suggests a revision of long-standing views on the impact of age-related brain shrinkage.
BioMarker Strategies received a $1.5 million SBIR award to develop a pathway-based companion diagnostic test to facilitate the selection of optimal therapy for patients with melanoma. This award was preceded by an NCI award of $200,000 almost two years ago in September 2011.
Research led by SUNY Downstate Medical Center has identified a brain receptor that appears to initiate adolescent synaptic pruning, a process believed necessary for learning, but one that appears to go awry in both autism and schizophrenia.
AstraZeneca today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS).
Johns Hopkins scientists have identified a molecular marker called "Mig 6" that appears to accurately predict longer survival - up to two years - among patients prescribed two of the most widely used drugs in a class of anticancer agents called EGFR inhibitors.
› Verified 5 days ago
Sameer Desai, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 411 W Randolph Rd, Hopewell, VA 23860 Phone: 804-289-4500 | |
Sandra Simons, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 411 W Randolph Rd, Hopewell, VA 23860 Phone: 804-452-3624 | |
Anant Singh, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 411 W Randolph Rd, Hopewell, VA 23860 Phone: 804-330-2000 | |
Nilda Jo Tensen, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 411 W Randolph Rd, Hopewell, VA 23860 Phone: 804-452-3624 Fax: 804-452-2827 | |
Sonja Wilkey, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 411 W Randolph Rd, Hopewell, VA 23860 Phone: 804-330-2000 | |
Sri Loganathan, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 411 W Randolph Rd, Hopewell, VA 23860 Phone: 804-452-3624 |